Does the media prefer VVOS or NMTC?

In the previous week, Vivos Therapeutics had 2 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 3 mentions for Vivos Therapeutics and 1 mentions for NeuroOne Medical Technologies. Vivos Therapeutics' average media sentiment score of 0.75 beat NeuroOne Medical Technologies' score of 0.00 indicating that Vivos Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vivos Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NeuroOne Medical Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CTSO or VVOS?

In the previous week, Vivos Therapeutics had 2 more articles in the media than Cytosorbents. MarketBeat recorded 3 mentions for Vivos Therapeutics and 1 mentions for Cytosorbents. Vivos Therapeutics' average media sentiment score of 0.75 beat Cytosorbents' score of 0.00 indicating that Vivos Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytosorbents 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vivos Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend VVOS or PETV?

Vivos Therapeutics currently has a consensus price target of $2.80, suggesting a potential upside of 223.89%. Given Vivos Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Vivos Therapeutics is more favorable than PetVivo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vivos Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 PetVivo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is VVOS or PETV more profitable?

Vivos Therapeutics has a net margin of -127.70% compared to PetVivo's net margin of -902.82%. Vivos Therapeutics' return on equity of -2,325.64% beat PetVivo's return on equity. Company Net Margins Return on Equity Return on Assets Vivos Therapeutics -127.70% -2,325.64% -98.12% PetVivo -902.82% -4,813.07% -281.78%

Is FEMY or VVOS more profitable?

Vivos Therapeutics has a net margin of -127.70% compared to Femasys' net margin of -521.97%. Femasys' return on equity of -258.08% beat Vivos Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Femasys -521.97% -258.08% -73.72% Vivos Therapeutics -127.70% -2,325.64% -98.12%

Does the media favor FEMY or VVOS?

In the previous week, Femasys and Femasys both had 3 articles in the media. Femasys' average media sentiment score of 0.76 beat Vivos Therapeutics' score of 0.75 indicating that Femasys is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Femasys 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vivos Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Vivos Therapeutics (VVOS) Competitors

$0.86 +0.17 (+24.84%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$0.82 -0.05 (-5.73%)

As of 06/5/2026 07:59 PM Eastern

Compare

VVOS vs. MLSS, NMTC, CTSO, PETV, and FEMY

Should you buy Vivos Therapeutics stock or one of its competitors? MarketBeat compares Vivos Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vivos Therapeutics include Milestone Scientific (MLSS), NeuroOne Medical Technologies (NMTC), Cytosorbents (CTSO), PetVivo (PETV), and Femasys (FEMY). These companies are all part of the "medical equipment" industry.

How does Vivos Therapeutics compare to Milestone Scientific?

Vivos Therapeutics (NASDAQ:VVOS) and Milestone Scientific (NYSE:MLSS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings, media sentiment and valuation.

Milestone Scientific has lower revenue, but higher earnings than Vivos Therapeutics. Milestone Scientific is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$17.44M	0.69	-$21.17M	-$2.14	N/A
Milestone Scientific	$8.90M	4.11	-$6.93M	-$0.05	N/A

Vivos Therapeutics has a beta of 6.1, meaning that its stock price is 510% more volatile than the broader market. Comparatively, Milestone Scientific has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market.

In the previous week, Vivos Therapeutics had 3 more articles in the media than Milestone Scientific. MarketBeat recorded 3 mentions for Vivos Therapeutics and 0 mentions for Milestone Scientific. Vivos Therapeutics' average media sentiment score of 0.75 beat Milestone Scientific's score of 0.00 indicating that Vivos Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Vivos Therapeutics	Positive
Milestone Scientific	Neutral

Milestone Scientific has a net margin of -52.01% compared to Vivos Therapeutics' net margin of -127.70%. Milestone Scientific's return on equity of -60.26% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-127.70%	-2,325.64%	-98.12%
Milestone Scientific	-52.01%	-60.26%	-40.23%

Vivos Therapeutics presently has a consensus target price of $2.80, indicating a potential upside of 223.89%. Milestone Scientific has a consensus target price of $1.00, indicating a potential upside of 140.79%. Given Vivos Therapeutics' higher possible upside, analysts clearly believe Vivos Therapeutics is more favorable than Milestone Scientific.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Milestone Scientific	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

26.4% of Vivos Therapeutics shares are held by institutional investors. Comparatively, 5.8% of Milestone Scientific shares are held by institutional investors. 2.1% of Vivos Therapeutics shares are held by company insiders. Comparatively, 12.5% of Milestone Scientific shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Vivos Therapeutics and Milestone Scientific tied by winning 8 of the 16 factors compared between the two stocks.

How does Vivos Therapeutics compare to NeuroOne Medical Technologies?

Vivos Therapeutics (NASDAQ:VVOS) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

In the previous week, Vivos Therapeutics had 2 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 3 mentions for Vivos Therapeutics and 1 mentions for NeuroOne Medical Technologies. Vivos Therapeutics' average media sentiment score of 0.75 beat NeuroOne Medical Technologies' score of 0.00 indicating that Vivos Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vivos Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NeuroOne Medical Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NeuroOne Medical Technologies has a net margin of -68.35% compared to Vivos Therapeutics' net margin of -127.70%. NeuroOne Medical Technologies' return on equity of -98.33% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-127.70%	-2,325.64%	-98.12%
NeuroOne Medical Technologies	-68.35%	-98.33%	-69.85%

NeuroOne Medical Technologies has lower revenue, but higher earnings than Vivos Therapeutics. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$17.44M	0.69	-$21.17M	-$2.14	N/A
NeuroOne Medical Technologies	$12.10M	2.45	-$3.61M	-$0.85	N/A

Vivos Therapeutics currently has a consensus target price of $2.80, suggesting a potential upside of 223.89%. NeuroOne Medical Technologies has a consensus target price of $11.67, suggesting a potential upside of 239.15%. Given NeuroOne Medical Technologies' stronger consensus rating and higher possible upside, analysts plainly believe NeuroOne Medical Technologies is more favorable than Vivos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
NeuroOne Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

26.4% of Vivos Therapeutics shares are held by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are held by institutional investors. 2.1% of Vivos Therapeutics shares are held by company insiders. Comparatively, 11.8% of NeuroOne Medical Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Vivos Therapeutics has a beta of 6.1, indicating that its stock price is 510% more volatile than the broader market. Comparatively, NeuroOne Medical Technologies has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market.

Summary

NeuroOne Medical Technologies beats Vivos Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Vivos Therapeutics compare to Cytosorbents?

Cytosorbents (NASDAQ:CTSO) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.

Cytosorbents has higher revenue and earnings than Vivos Therapeutics. Cytosorbents is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytosorbents	$37.06M	0.78	-$8.20M	-$0.19	N/A
Vivos Therapeutics	$17.44M	0.69	-$21.17M	-$2.14	N/A

32.9% of Cytosorbents shares are held by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are held by institutional investors. 7.3% of Cytosorbents shares are held by company insiders. Comparatively, 2.1% of Vivos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Vivos Therapeutics had 2 more articles in the media than Cytosorbents. MarketBeat recorded 3 mentions for Vivos Therapeutics and 1 mentions for Cytosorbents. Vivos Therapeutics' average media sentiment score of 0.75 beat Cytosorbents' score of 0.00 indicating that Vivos Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytosorbents	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vivos Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cytosorbents presently has a consensus price target of $5.38, indicating a potential upside of 1,071.02%. Vivos Therapeutics has a consensus price target of $2.80, indicating a potential upside of 223.89%. Given Cytosorbents' higher possible upside, equities research analysts plainly believe Cytosorbents is more favorable than Vivos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Cytosorbents has a net margin of -31.85% compared to Vivos Therapeutics' net margin of -127.70%. Cytosorbents' return on equity of -235.57% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytosorbents	-31.85%	-235.57%	-37.88%
Vivos Therapeutics	-127.70%	-2,325.64%	-98.12%

Cytosorbents has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market. Comparatively, Vivos Therapeutics has a beta of 6.1, meaning that its share price is 510% more volatile than the broader market.

Summary

Cytosorbents beats Vivos Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Vivos Therapeutics compare to PetVivo?

Vivos Therapeutics (NASDAQ:VVOS) and PetVivo (NASDAQ:PETV) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

Vivos Therapeutics currently has a consensus price target of $2.80, suggesting a potential upside of 223.89%. Given Vivos Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Vivos Therapeutics is more favorable than PetVivo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
PetVivo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Vivos Therapeutics has a beta of 6.1, indicating that its stock price is 510% more volatile than the broader market. Comparatively, PetVivo has a beta of 1.25, indicating that its stock price is 25% more volatile than the broader market.

Vivos Therapeutics has a net margin of -127.70% compared to PetVivo's net margin of -902.82%. Vivos Therapeutics' return on equity of -2,325.64% beat PetVivo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-127.70%	-2,325.64%	-98.12%
PetVivo	-902.82%	-4,813.07%	-281.78%

26.4% of Vivos Therapeutics shares are owned by institutional investors. Comparatively, 24.5% of PetVivo shares are owned by institutional investors. 2.1% of Vivos Therapeutics shares are owned by company insiders. Comparatively, 10.8% of PetVivo shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

PetVivo has lower revenue, but higher earnings than Vivos Therapeutics. PetVivo is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$17.44M	0.69	-$21.17M	-$2.14	N/A
PetVivo	$1.05M	25.42	-$10.95M	-$0.38	N/A

In the previous week, Vivos Therapeutics had 3 more articles in the media than PetVivo. MarketBeat recorded 3 mentions for Vivos Therapeutics and 0 mentions for PetVivo. Vivos Therapeutics' average media sentiment score of 0.75 beat PetVivo's score of 0.00 indicating that Vivos Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Vivos Therapeutics	Positive
PetVivo	Neutral

Summary

Vivos Therapeutics beats PetVivo on 12 of the 16 factors compared between the two stocks.

How does Vivos Therapeutics compare to Femasys?

Femasys (NASDAQ:FEMY) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and profitability.

Vivos Therapeutics has a net margin of -127.70% compared to Femasys' net margin of -521.97%. Femasys' return on equity of -258.08% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Femasys	-521.97%	-258.08%	-73.72%
Vivos Therapeutics	-127.70%	-2,325.64%	-98.12%

Femasys has higher earnings, but lower revenue than Vivos Therapeutics. Femasys is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$2.38M	7.78	-$18.63M	-$0.27	N/A
Vivos Therapeutics	$17.44M	0.69	-$21.17M	-$2.14	N/A

Femasys has a beta of -2.23, indicating that its share price is 323% less volatile than the broader market. Comparatively, Vivos Therapeutics has a beta of 6.1, indicating that its share price is 510% more volatile than the broader market.

In the previous week, Femasys and Femasys both had 3 articles in the media. Femasys' average media sentiment score of 0.76 beat Vivos Therapeutics' score of 0.75 indicating that Femasys is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Femasys	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vivos Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Femasys currently has a consensus target price of $5.33, indicating a potential upside of 1,640.64%. Vivos Therapeutics has a consensus target price of $2.80, indicating a potential upside of 223.89%. Given Femasys' stronger consensus rating and higher probable upside, equities analysts plainly believe Femasys is more favorable than Vivos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

65.3% of Femasys shares are held by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are held by institutional investors. 7.6% of Femasys shares are held by company insiders. Comparatively, 2.1% of Vivos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Femasys beats Vivos Therapeutics on 11 of the 15 factors compared between the two stocks.

Get Vivos Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VVOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VVOS vs. The Competition

Export

Metric	Vivos Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$9.62M	$2.98B	$6.46B	$12.44B
Dividend Yield	N/A	1.70%	2.68%	5.34%
P/E Ratio	-0.40	17.86	23.69	23.63
Price / Sales	0.69	434.61	542.55	125.33
Price / Cash	N/A	56.21	42.35	57.17
Price / Book	-5.40	3.83	9.73	6.37
Net Income	-$21.17M	$75.85M	$3.56B	$337.36M
7 Day Performance	23.50%	-1.79%	-2.92%	-2.39%
1 Month Performance	20.09%	-7.61%	-0.85%	-0.58%
1 Year Performance	-61.23%	14.99%	22.23%	25.53%

Vivos Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VVOS Vivos Therapeutics	3.1376 of 5 stars	$0.86 +24.8%	$2.80 +223.9%	-60.9%	$9.62M	$17.44M	N/A	160	News Coverage Analyst Forecast High Trading Volume
MLSS Milestone Scientific	N/A	$0.37 -2.8%	$1.00 +168.7%	-54.0%	$32.77M	$8.90M	N/A	30	Gap Down
NMTC NeuroOne Medical Technologies	1.9715 of 5 stars	$3.87 +4.9%	$11.67 +201.5%	-2.7%	$31.81M	$9.72M	N/A	20	News Coverage Short Interest Increase
CTSO Cytosorbents	1.5487 of 5 stars	$0.46 +0.4%	$5.38 +1,061.9%	-56.3%	$28.94M	$37.06M	N/A	220	Gap Down
PETV PetVivo	N/A	$0.79 +1.3%	N/A	-5.2%	$28.51M	$1.05M	N/A	20	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VVOS) was last updated on 6/6/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vivos Therapeutics (VVOS) Competitors

VVOS vs. MLSS, NMTC, CTSO, PETV, and FEMY

How does Vivos Therapeutics compare to Milestone Scientific?

Summary

How does Vivos Therapeutics compare to NeuroOne Medical Technologies?

Summary

How does Vivos Therapeutics compare to Cytosorbents?

Summary

How does Vivos Therapeutics compare to PetVivo?

Summary

How does Vivos Therapeutics compare to Femasys?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VVOS vs. The Competition

Vivos Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vivos Therapeutics (VVOS) Competitors

VVOS vs. MLSS, NMTC, CTSO, PETV, and FEMY

How does Vivos Therapeutics compare to Milestone Scientific?

Which has preferable valuation & earnings, VVOS or MLSS?

Which has more volatility and risk, VVOS or MLSS?

Does the media favor VVOS or MLSS?

Is VVOS or MLSS more profitable?

Do analysts prefer VVOS or MLSS?

Do insiders and institutionals believe in VVOS or MLSS?

Summary

How does Vivos Therapeutics compare to NeuroOne Medical Technologies?

Does the media prefer VVOS or NMTC?

Is VVOS or NMTC more profitable?

Which has better earnings & valuation, VVOS or NMTC?

Do analysts prefer VVOS or NMTC?

Do insiders and institutionals have more ownership in VVOS or NMTC?

Which has more risk & volatility, VVOS or NMTC?

Summary

How does Vivos Therapeutics compare to Cytosorbents?

Which has better earnings & valuation, CTSO or VVOS?

Do institutionals and insiders believe in CTSO or VVOS?

Does the media refer more to CTSO or VVOS?

Do analysts recommend CTSO or VVOS?

Is CTSO or VVOS more profitable?

Which has more volatility & risk, CTSO or VVOS?

Summary

How does Vivos Therapeutics compare to PetVivo?

Do analysts recommend VVOS or PETV?

Which has more volatility & risk, VVOS or PETV?

Is VVOS or PETV more profitable?

Do insiders and institutionals hold more shares of VVOS or PETV?

Which has preferable earnings & valuation, VVOS or PETV?

Does the media prefer VVOS or PETV?

Summary

How does Vivos Therapeutics compare to Femasys?

Is FEMY or VVOS more profitable?

Which has preferable earnings and valuation, FEMY or VVOS?

Which has more volatility and risk, FEMY or VVOS?

Does the media favor FEMY or VVOS?

Do analysts rate FEMY or VVOS?

Do institutionals & insiders hold more shares of FEMY or VVOS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VVOS vs. The Competition

Vivos Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools